Curaleaf Holdings - CEO, Joseph Lusardi
CEO, Joseph Lusardi
Source: The Green Fund
Market Herald logo


Be the first with the news that moves the market
  • Curaleaf Holdings (CSE:CURA) has been approved as a Clinical Registrant in the US state of Pennsylvania
  • The approval was issued by the Commonwealth’s Department of Health, Office of Medical Marijuana
  • Under the medical marijuana research program Curaleaf will be free to open a cultivation and processing facility, and up to six dispensaries
  • Shares in the company are currently down 0.88 per cent to C$7.91, with a market cap of C$3.73 billion

Curaleaf Holdings (CSE:CURA) has announced its approval as a Clinical Registrant in Pennsylvania.

The company is a multi-state cannabis operator, with operations on both the East and West coasts of the United States.

Issued by the Department of Health, the approval will allow Curaleaf to open a cultivation and processing facility, and up to six dispensaries in the state.

In turn, the company will support research initiatives via the provision of medical cannabis, general expertise and distribution to relevant patients.

“This research is essential to providing physicians with more evidence-based research to make clinical decisions for their patients,” said the Department of Health’s Dr. Rachel Levine.

“It is the cornerstone of our program and the key to our clinically based, patient- focused program for those suffering with cancer, PTSD and other serious medical conditions.”

Curaleaf currently operates 53 dispensaries in 14 US states, with 15 cultivation and 24 processing sites.

The company’s CEO, Joseph Lusardi, thanked the Pennsylvania Department of Health and confirmed the company’s commitment to research and medical patients.

“Curaleaf has always been focused on high-quality cannabis products, as well as superior patient care and education,” he said.

“We look forward to contributing to medical research that will ultimately benefit not only the residents of the Commonwealth, but the entire country.”

Shares in Curaleaf are currently down 0.88 per cent to C$7.91, with a market cap of C$3.73 billion.

More From The Market Herald
BioHarvest - CEO, Ilan Sobel

" BioHarvest Sciences (CSE:BHSC) exploring opportunities to sell its cannabis products in the Canadian market

BioHarvest Sciences (BHSC) is exploring opportunities to acquire an existing licensed facility or a Licensed Producer in Canada.
HEXO - CEO, Scott Cooper.

" HEXO (TSX:HEXO) delineates its path forward

HEXO (HEXO) has announced cost-saving initiatives to carry the company into the future.

" Tinley’s (CSE:TNY) makes production announcement, closes first tranche of private placement

The Tinley Beverage Company (TNY) will begin making Green Monké products at its Long Beach facility.

" Tinley (CSE:TNY) announces first product clearance under California distribution license

The Tinley Beverage Company (TNY) has released an update regarding products manufactured at its Long Beach facility.